ES Cell Gene Targeting
Cyagen’s ES Cell Gene Targeting platform leverages homologous recombination in murine embryonic stem (ES) cells to deliver highly precise, complex gene modifications. It is ideal for conditional knockouts, reporter knockins, humanized models, and large-fragment insertions.
No Off-Target Concerns
Ideal for sensitive applications with zero nuclease-related off-target risks.
Complex Edits Made Easy
Enables large-fragment knockins and humanization—up to ~20 kb or more.
Trusted Precision
Decades-proven ES cell targeting ensures accurate and reliable gene edits.
Technology
Applications
FAQs
How ES Cell Gene Targeting Works
ES Cell Gene Targeting introduces specific genetic modifications by
homologous recombination within embryonic stem (ES) cells. The
engineered ES cells are then injected into blastocysts to generate
chimeric mice, which transmit the desired allele through the germline.
While this traditional method requires longer timelines compared to
newer editing technologies, it remains uniquely suited for complex
edits, especially those involving large DNA fragments or sophisticated
genetic constructs.
| Feature | ES Cell Gene Targeting | TurboKnockout® (Enhanced) | Targeted Gene Editing |
|---|---|---|---|
| Turnaround Time | 10-14 months | 6-8 months | 5-7 months |
| Approach | ES Cell-mediated HR | Proprietary ESC + self-deleting cassette | Embryo-stage nuclease targeting |
| Max Knockin Size | ~20 kb (RMCE: ~300 kb) | ~20 kb (RMCE: ~300 kb) | ≤15 kb |
| Off-target Risk | None | None | Moderate |
| Screening Method | PCR + Southern Blot | PCR + Southern Blot | PCR + Sequencing |
| Applications | KO, cKO, Point Mutation, KI, Humanization | KO, cKO, KI, Humanization | KO, cKO, Point Mutation |
| Patent Risk | Low | None | High (restricted regions) |
Looking for a faster and more efficient alternative?
Explore TurboKnockout® – Our Next-Generation ES
Cell Targeting Technology →
Citation Database
Molecular Therapy: Methods & Clinical Development, March, 2025
Intracranial AAV administration dose-dependently recruits B cells to inhibit the AAV redosing
【Other】
Gut, February, 2025
E-twenty-six-specific sequence variant 5 (ETV5) facilitates hepatocellular carcinoma progression and metastasis through enhancing polymorphonuclear myeloid-derived suppressor cell (PMN-MDSC)-mediated immunosuppression
【Other】
Cell Death & Disease, February, 2025
Mcm5 mutation leads to silencing of Stat1-bcl2 which accelerating apoptosis of immature T lymphocytes with DNA damage
【Other】
Molecular Therapy, February, 2025
Single-cell data-driven design of armed oncolytic virus to boost cooperative innate-adaptive immunity against cancer
【Other】
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.